Work

In-vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates

Year: 2026

Type: article

Abstract: values of 0.38 μg/ml and 0.5 μg/ml, respectively, and 98.3% susceptibility. These findings support levonadifloxacin as a promising therapeutic option for MRSA infections.

Source: Indian Journal of Medical Microbiology

DOI: 10.1016/j.ijmmb.2026.101112

Authors: Sukriti Yadav, Imola Jamir, Vishal Kumar Singh, Shubhangi Kansal, Archana Angrup, Neelam Taneja

Institutions: All India Institute of Medical Sciences Rishikesh, Post Graduate Institute of Medical Education and Research

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,210

Funder: Wockhardt

OpenAlex ID: W7151102433

FWCI:

Cites: 15

Cited by:

Related to: